Bleomycins are a group of antibiotics with antitumor activity.
Their DNA-cleaving mechanism and toxicity profiles are complex and not fully understood.
Purpose of the Study:
To elucidate the structural components of bleomycins responsible for DNA strand scission.
To investigate the relationship between bleomycin structure and its associated toxicities (renal and pulmonary).
To identify the bleomycin-inactivating enzyme and explore its role in therapeutic efficacy and toxicity.
Main Methods:
Structural analysis of bleomycins and related compounds.
In vitro studies on SV40 viral DNA strand scission.
In vivo toxicity studies in dogs and mice.
Enzyme assays to characterize bleomycin-inactivating enzyme activity.
Cell growth inhibition assays with bleomycin and enzyme inhibitors.
Main Results:
The beta-aminoalanine amide moiety and carbamoyl group are crucial for bleomycin's DNA strand scission activity.
Multiple guanido groups in terminal amines correlate with irreversible renal toxicity in dogs.
Pulmonary toxicity is dependent on specific terminal amine structures.
A novel aminopeptidase B was identified as the enzyme inactivating bleomycin by hydrolyzing the beta-aminoalanine amide group.
Lower levels of this enzyme in squamous cell carcinoma cells may contribute to bleomycin's efficacy against this cancer.
Inhibition of this enzyme potentiated bleomycin's anti-cancer effects, suggesting intracellular enzyme action.
Bleomycin 5033 demonstrated comparable efficacy and lower toxicity to current bleomycin treatments, while Bleomycin A5196 showed enhanced activity and toxicity but reduced lung toxicity.
Conclusions:
Bleomycin's DNA-damaging activity is linked to specific structural features.